REYON PHARMACEUTICAL CO., LTD
Financials
Valuation Metrics
REYON PHARMACEUTICAL CO., LTD's Market Cap is ₩1849B. At end of 2025 it was ₩2004B. Ranked #843 of 2,436 in KR market (top 35%), #460 of 787 on KOSPI (top 58%), #91 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 39%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 184.94B KRW | KR#843/2,436 Sec#91/234 |
| Revenue | 145.22B KRW | KR#1,176/2,436 Sec#71/234 |
| Net Income | -40.59B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 454.38B KRW | KR#790/2,436 Sec#48/234 |
| Net Assets | 209.58B KRW | KR#902/2,436 Sec#64/234 |
| Employees | 449 | KR#544/2,436 Sec#43/234 |
| Value | ||
| P/B | 0.88x | KR#1,419/2,436 Sec#89/234 |
| P/S | 1.27x | KR#1,597/2,436 Sec#92/234 |
| FCF Yield | -3.49% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -19.37% | KR#2,063/2,436 Sec#162/234 |
| ROA | -8.93% | KR#2,046/2,436 Sec#155/234 |
| Op. Margin | -22.81% | KR#2,146/2,436 Sec#145/234 |
| Revenue Growth | -1.92% | KR#1,546/2,436 Sec#148/234 |
| Earnings Growth | -5068.68% | KR#1,744/2,436 Sec#122/234 |
| Financial Health | ||
| Debt Ratio | 216.80% | KR#1,819/2,436 Sec#197/234 |
| Total Debt | 217.88B KRW | KR#466/2,436 Sec#23/234 |
| FCF | -6.46B KRW | KR#1,575/2,436 Sec#125/234 |
| Cash | 4.29B KRW | KR#2,054/2,436 Sec#188/234 |
| Current Ratio | 0.52x | KR#2,245/2,436 Sec#215/234 |
| Dividend | ||
| Div. Yield | 1.50% | KR#1,041/2,436 Sec#57/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -11.87% | KR#930/2,436 Sec#67/234 |
| 1M Return | -2.16% | KR#827/2,436 Sec#64/234 |
| From 52W High | -24.62% | KR#243/2,436 Sec#13/234 |
| 1Y MDD | -28.87% | KR#180/2,436 Sec#9/234 |
| Trading | ||
| Volume | 33,260 shares | KR#1,876/2,436 Sec#182/234 |
| Foreign Own. | 1.17% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -2,184 KRW | KR—/2,436 Sec—/234 |
| BPS | 11,427 KRW | KR#855/2,436 Sec#62/234 |
Company Info
Headquartered in Gangnam-gu, Seoul, E-Yang Pharmaceutical was established in 1964, promoting the domestic production of pharmaceutical raw materials and expanding into new technology business finance in 2017. The company holds various prescription medicines for multiple indications, exclusively supplies original medicines like Optiray, and sells active pharmaceutical ingredients such as Tacrolimus. To become a global bio & chemical pharmaceutical company, it collaborates with bio-ventures on new drug development, with its KGMP-certified Chungju factory driving an R&D business model.